Allarity Therapeutics, Inc.

Develops personalized cancer drugs using a diagnostic platform to predict patient response.

ALLR | US

Overview

Corporate Details

ISIN(s):: US0167445008
LEI:
Country:: United States of America
Address:: 24 SCHOOL ST., 2ND FLOOR, 2108 BOSTON
Website:: https://allarity.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Allarity Therapeutics, Inc. is a clinical-stage precision medicine company focused on developing personalized cancer treatments. The company leverages its proprietary Drug Response Predictor (DRP®) technology, a diagnostic platform that analyzes tumor biology to predict a patient's response to specific therapies. This approach aims to refine patient selection and improve clinical outcomes for its pipeline of in-licensed oncology therapeutics. Allarity's lead clinical program is stenoparib, an orally available, dual-action small molecule inhibitor being advanced for patients with advanced recurrent ovarian cancer. The company's mission is to enhance patient outcomes through data-driven decision-making and personalized cancer care.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Allarity Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Allarity Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Allarity Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
NeoImmuneTech, Inc. Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.	United States of America	950220
NEONC TECHNOLOGIES HOLDINGS, INC. Developing intranasal drug delivery to treat brain cancer & CNS diseases by crossing the BBB.	United States of America	NTHI
Neumora Therapeutics, Inc. Developing data-driven precision medicines for neuropsychiatric and neurodegenerative disorders.	United States of America	NMRA
Neuphoria Therapeutics Inc. Develops novel ion channel modulators for treating neuropsychiatric disorders like anxiety & PTSD.	United States of America	NEUP
NEUROCRINE BIOSCIENCES INC Develops therapies for neurological, neuroendocrine, and neuropsychiatric disorders.	United States of America	NBIX
Neurogene Inc. Developing genetic medicines using gene therapy for rare and devastating neurological diseases.	United States of America	NGNE
NeuroSense Therapeutics Ltd. Developing combination therapies for neurodegenerative diseases, with a focus on ALS.	United States of America	NRSN
NewAmsterdam Pharma Co N.V. Developing oral LDL-lowering therapies for high-risk cardiovascular disease patients.	United States of America	NAMS
Newbury Pharmaceuticals AB Develops specialty prescription drugs for Scandinavia in oncology, rare diseases & neurology.	Sweden	NEWBRY
New Nordic Healthbrands AB Develops and markets herbal supplements & beauty products for natural wellness consumers globally.	Sweden	NNH